Riskpilot← Back to searchSign inGet full accessERCO Pharma AB
ABActiveOrg 5569811887Nybrogatan 17Research and experimental development on natural sciences and engineering · NACE 7210Est. 20140 employees
Revenue 2024
SEK 699
-100% vs 2023
EBITDA margin
-13460.1%
+97% vs 2023
Equity ratio
87.1%
Financial strength
Net profit 2024
SEK -94K
+97% vs 2023
| Revenue | SEK 699 | -100% |
| EBITDA | SEK -94K | +97% |
| Net profit | SEK -94K | +97% |
| Total assets | SEK 81K | -27% |
| Equity | SEK 71K | +28% |
| Employees | 0 | — |
Legal name
ERCO Pharma AB
Org number
5569811887
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
29 augusti 2014
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva utveckling, tillverkning och försäljning av läkemedel och medicinska hjälpmedel, relaterade tjänster och därmed förenlig verksamhet.
Address
Nybrogatan 17
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | −524 | −416 | 1 |
| Staff expenses | — | — | −1 721 | −1 385 | −44 |
| EBITDA | −2 893 | −3 175 | −4 932 | −2 983 | −94 |
| Depreciation & amort. | −269 | −222 | −37 | −37 | — |
| EBIT | −3 162 | −3 397 | −4 970 | −3 020 | −94 |
| Net financials | — | — | 0 | 0 | −0 |
| Profit before tax | 1 | 4 | 0 | −3 020 | −94 |
| Tax | −0 | −1 | −0 | — | — |
| Net profit | 1 | 3 | 0 | −3 020 | −94 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 451 | 267 | 1 150 | 111 | 81 |
| Equity | 49 | 52 | 52 | 55 | 71 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 378 | 215 | 1 098 | 56 | 10 |
| Total debt | 378 | 215 | 1 098 | 56 | 10 |
EBITDA margin
-13460.1%
This company
15.8%
Market median
-85291% vs market
20202024
Equity ratio
87.1%
This company
38.2%
Market median
+128% vs market
20202024
Return on equity
-132.9%
This company
18.4%
Market median
-822% vs market
20202024
Net profit margin
-13499.4%
This company
8.1%
Market median
-166759% vs market
20202024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20202024
Debt / equity
0.15×
This company
0.62×
Market median
+76% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CV Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (1) | ||
MG External Signatory | External Signatory | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 66% | 66% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Dirbal Aktiebolag
ERCO Pharma AB Board members of ERCO Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maris Gunars Normunds Hartmanis | External Signatory | 0 companies |
| Clara Veronica Sandman | Chief Executive Officer | 0 companies |
| Adriana Bjäringer | Deputy Board Member | 0 companies |
| Mats Oskar Hedgårdh | Deputy Board Member | 0 companies |